Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094743 · ClinicalTrials.gov registry record · NA
Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens
A NA study, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT01094743: Completed NA study, sponsored by Johnson & Johnson Vision Care.
NCT01094743 is a NA study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01094743, a NA study, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to compare visual acuity and redness of eyes between a prototype contact lens and an already marketed contact lens.
Primary Outcome
Snellen monocular visual acuity measurement
Interventions
- DEVICE galyfilcon A prototype lens
- DEVICE lotrafilcon B lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2010-03-01 |
| Phase | NA |
What the finished NCT01094743 record still lists
NCT01094743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which galyfilcon A prototype lens is the first listed.
NCT01094743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01094743 about?
NCT01094743 is a clinical study titled "Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens". The purpose of this study is to compare visual acuity and redness of eyes between a prototype contact lens and an already marketed contact lens.
What is the current status of trial NCT01094743?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2010-02-01. Estimated completion is 2010-03-01.
What interventions are being tested in trial NCT01094743?
The interventions under investigation include: galyfilcon A prototype lens (DEVICE), lotrafilcon B lens (DEVICE).
Who is sponsoring clinical trial NCT01094743?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01094743's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI